key: cord-0987332-0b14ocyt
authors: Issa, Nahéma; Dumery, Margot; Guisset, Olivier; Mourissoux, Gaelle; Bonnet, Fabrice; Camou, Fabrice
title: Feasibility of Tocilizumab in ICU patients with COVID‐19
date: 2020-06-02
journal: J Med Virol
DOI: 10.1002/jmv.26110
sha: 52f9a1d81cf72f35863d390a0d1e4fd65fec4dae
doc_id: 987332
cord_uid: 0b14ocyt

Severe COVID‐19 causes cytokine release syndrome and is associated with high mortality. In this retrospective case series, all patients diagnosed with COVID‐19 by semi quantitative RT‐PCR and hyperinflammatory markers were treated with tocilizumab. The use of tocilizumab was associated with rapid apyrexia, improvement of respiratory, biological parameters and short length of hospitalization (11 days). Moreover, no adverse effect attributed to the treatment was noticed. Tocilizumab seems to be a promising and safe therapy in severe patients. This article is protected by copyright. All rights reserved.

Nahéma ISSA 2 The optimal treatment strategy of COVID 19 in ICU is still unclear. Symptoms similar to cytokine release syndrome (CRS) have been described in the literature and have been associated with severe and fatal issue in patients with COVID 19. Many authors suggest that all patients with severe COVID should be screened for hyper inflammation using laboratory trends to identify the subgroup from which specific anti-inflammatory drugs such as IL-6 receptor inhibitor could decrease ARDS and mortality [1, 2] . We read with interest several case series published in J Med Virol about tocilizumab and COVID-19 and present our results to describe the outcome of severe patients treated with tocilizumab and its safety in a real-life practice [3] [4] [5] [6] [7] . In this retrospective case series, all patients diagnosed with COVID-19 by semi quantitative RT-PCR on nasopharyngeal swabs, admitted in an ICU between March This article is protected by copyright. All rights reserved. tocilizumab (8mg/kg) was decided in case of increase of inflammatory parameters (at least 2 among: fibrinogen > 8g/L, ferritin > 1,000ng/mL, D-Dimers > 3,000ng/ml and CRP > 150mg/L), persistent fever (tympanic temperature ≥ 38°1 during 24h) and/or pulmonary involvement (ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ) of less than 300mmHg) in the first 5 days. When QTc was below 460ms, patients received hydroxychloroquine, ceftriaxone and respiratory support adapted with clinical state. Ten men with a median age of 66 years were included: 7/10 had, at least, one cardiovascular comorbidity (6 had hypertension and 3 had diabetes). The median SAPS II was 29. Median time between first symptoms of COVID 19 and ICU admission was 7 days (2 to 10). All patients were febrile and seven patients required invasive ventilation included one before tocilizumab. In eight patients, chest CT-scan showed bilateral ground glass opacities. Median PaO 2 /FiO 2 was 156mmHg at admission, 94mmHg before tocilizumab and 230mmHg three days later. Median time between ICU admission and tocilizumab administration was three days. All patients received concomitant treatment by hydroxychloroquine and three of them got hydrocortisone in addition to restore hemodynamic stability. Median values of inflammatory parameters before tocilizumab were: CRP = 246 mg/L; fibrinogen = 10g/L; D-Dimers = 1,354ng/mL, and ferritin = 2,751ng/mL. Apyrexia was obtained three hours after tocilizumab infusion in median. At day 3, CRP and fibrinogen decreased of 83% (43mg/L) and 40% (6g/L), respectively (Table 1) . Median length of stay in ICU was 11 days. One patient still needed invasive ventilation at day 14 and one patient died at day 4 (pulmonary embolism). Two patients who received hydrocortisone had infectious complications: one aspergillosis and one bacterial ventilator-associated pneumonia due to Serratia. No adverse drug reaction attributed This article is protected by copyright. All rights reserved.

to tocilizumab was reported. This case series of ten patients confirms the safety of the use of tocilizumab for treatment of COVID-19 CRS in the context of ICU. CRP and fibrinogen can be used to guide tocilizumab prescription early in patient admitted to ICU for acute respiratory symptoms or CRS. The use of tocilizumab was associated with rapid apyrexia, improvement of respiratory and biological parameters and could reduce the length of hospitalization [8] . Tocilizumab is an interleukin 6 receptor inhibitor used for a long time for rheumatic diseases and more recently in CRS due to CAR T-cell associated toxicities. The use of tocilizumab was based on literature data suggesting that hospitalized patients with COVID-19 can develop a syndrome of dysregulated and systemic immune overactivation described as a cytokine storm or hyper inflammatory syndrome that worsens acute respiratory distress. Elevated IL-6 levels have been described in patients with severe COVID-19 and several case series have illustrated good outcomes with this treatment intravenously or subcutaneously [3] [4] [5] [6] [7] 9] . Moreover, recommendations from Italian intensivists (SIAARTI) already include IL-6 inhibitor for patients with severe COVID-19 [10]. Tocilizumab is most often well tolerated but may expose to adverse drug reactions such as elevation of hepatic transaminases, transient neutropenia, hypersensitivity reactions and intestinal perforation. So, patients should be carefully monitored. In practice, it is difficult to select the best candidates to benefit from tocilizumab therapy and the good timing.

Conversely to IL-6 plasmatic level, CRP and fibrinogen are two easily accessible markers that could be useful in critical patients. Our results need to be confirmed by controlled trials because of the limited number of patients. In severe and critical COVID-19 patients, cytokine storm is associated with acute respiratory distress and tocilizumab seems to be an effective and safe treatment in selective patients.

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine release syndrome in severe COVID-19

Tocilizumab for the treatment of severe coronavirus disease 2019

Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review

Tocilizumab in Patients with SARS-CoV-2 Infection

Tocilizumab treatment in COVID-19: A single center experience

Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

This article is protected by copyright. All rights reserved. disease 2019 outbreak: recommendations from clinical practice

D, day after tocilizumab infusion day, CRP C-reactive protein

Accepted Article